Companies /Healthcare

Envista Holdings Corp

NYSE: NVST Medical Instruments & Supplies
$27.28
▼ $0.31 (−1.12%) today
Markets closed · 8:00pm ET

Q2 2025 Earnings

Reported Jul 31, 2025, 4:12pm ET · SEC source
$0.26
Beat +13.54%
EPS · est. $0.23
$682.1M
Beat +6.53%
Revenue · est. $640.3M
−6.1%
Trailing market
NVST vs S&P since report
5 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−6%−3%0+3%Jul 31Aug 1report 4:12pm ETearnings−1.5%+4.7%
−6%−3%0+3%Jul 31Aug 1earnings−1.5%+4.7%
NVST +4.7%S&P 500 −1.5%
−6%−3%0+3%Jul 31Aug 1report 4:12pm ETearnings−1.8%+4.7%
−6%−3%0+3%Jul 31Aug 1earnings−1.8%+4.7%
NVST +4.7%NASDAQ −1.8%
−6%−3%0Jul 30Aug 8report 4:12pm ETearnings+1.0%−1.3%
−6%−3%0Jul 30Aug 8earnings+1.0%−1.3%
NVST −1.3%S&P 500 +1.0%
−6%−3%0Jul 30Aug 8report 4:12pm ETearnings+2.0%−1.3%
−6%−3%0Jul 30Aug 8earnings+2.0%−1.3%
NVST −1.3%NASDAQ +2.0%
+10.27%
Day of report
−1.68%
Next session
−2.83%
One week
−2.54%
30 days

S&P 500 over the same 30 days: +3.54%.

Did NVST Beat Earnings? Q2 2025 Results

Envista Holdings delivered a broad-based beat in the second quarter of fiscal 2025, with adjusted diluted EPS of $0.26 coming in 13.54% above the $0.23 consensus estimate and revenue of $682.10 million clearing expectations by 6.53% on 7.7% year-over-year growth. The dental products company swung to GAAP net income of $26.40 million from a $1.15 billion net loss in the year-ago period, which had been weighed down by a large goodwill and intangible asset impairment charge, while adjusted EBITDA surged 34% to $84.30 million as margin expanded 240 basis points to 12.4%. A key driver was gross margin improvement to 54.2% from 51.6%, fueled by operational gains and continued progress on Spark aligner margins through Envista's internal operating framework. Both the Specialty Products and Equipment segments contributed growth, with core sales rising 4.7% and 7.3%, respectively. Encouraged by first-half momentum, management raised its full-year core sales growth outlook to 3%-4% from 1%-3% and lifted adjusted diluted EPS guidance to $1.05-$1.15, though analysts offered a mixed reaction, lifting revenue forecasts while trimming per-share earnings estimates slightly.

Key Takeaways
  • 5.6% core sales growth across all major businesses and geographies
  • Adjusted EBITDA grew 34% year-on-year to $84 million with 240 bps margin expansion
  • Nobel Biocare returned to positive growth in North America
  • Continued improvement in Spark aligner margins through EBS methodology
  • Gross margin expanded to 54.2% from 51.6% year-over-year
  • Specialty Products & Technologies core sales growth of 4.7%
  • Equipment & Consumables core sales growth of 7.3%

“Envista achieved accelerated growth across all of our businesses and major geographies in the second quarter. This allowed us to further increase investments in growth, operations, and people, while also delivering strong improvement in year-over-year profitability. Based on the first half momentum and results, we are raising our full year guidance for 2025.”

Envista CEO, on the earnings call

Forward Guidance & Outlook

Envista raised its full-year 2025 guidance based on first-half momentum. Core sales growth is now expected at 3% to 4% (up from prior guidance of 1% to 3%). Adjusted EBITDA margin guidance is maintained at approximately 14%. Adjusted diluted EPS is now expected at $1.05 to $1.15 (up from prior guidance of $0.95 to $1.05).

NVST YoY Financials

Q2 2025 vs Q2 2024 · SEC filings Q2 2024 Q2 2025
$0$200.0M$400.0M$600.0M$633.1M$682.1MRevenue$329.9M$369.9MGross Profit$22.7M$46.3MOperating Income$13.1M$26.4MNet Income
$0$200.0M$400.0M$600.0MRevenueGross ProfitOperating IncomeNet Income

NVST Revenue by Segment

Specialty Products & Technologies$445.1M+7.2%
Equipment & Consumables$237.0M+8.7%

Figures from SEC filings and company reports. Not investment advice.